Maria M. M. Santos (0000-0002-2239-9353)

Personal information

Biography

M Santos graduated in Applied Chemistry (Organic Chemistry) at the New University of Lisbon (1994-1999). After a 3-months stay at the University Paris-Sud XI (Orsay, France) to develop a project in the area of catalysis (grant financed by the European Union), M Santos started a PhD in the field of Organic Synthesis at the New University of Lisbon (2000-2004). From 2004 to 2006, she was post-doc at the Amat-Bosch’s research group (University of Barcelona, Spain). In 2006, she returned to Portugal to join the group of Rui Moreira at the Faculty of Pharmacy of the University of Lisbon (FFUL) as a post-doctoral fellow.
In 2008, M Santos started her independent career at FFUL: “Science 2007 program” assistant researcher (2008-2013); “FCT Investigator program” assistant researcher (2013-2018); “CEEC individual program” principal researcher (2019-2020). Since 2021, M Santos is professor at the department of Pharmaceutical Sciences and Medicines (DCFM) of the FFUL. In 2023, M Santos was promoted to associate professor. M Santos leads the Medicinal Organic Chemistry Group at the Research Institute for Medicines, and the ultimate goal of her research is the development of general synthetic methods and strategies, and their application to the synthesis of bioactive molecules.

Activities

Collapse all

Universidade de Lisboa: Lisboa, PT

2023 to present | Associated Professor (Pharmaceutical Sciences and Medicines - Faculty of Pharmacy)

Employment

Maria M. M. Santos

https://orcid.org/0000-0002-2239-9353

Personal information

Emails & domains

Verified email addresses

Verified email domains

Websites & social links

Other IDs

Keywords

Countries

Biography

Activities

Employment (8)

Universidade de Lisboa: Lisboa, PT

Universidade de Lisboa: Lisboa, Lisboa, PT

Universidade de Lisboa: Lisboa, PT

Universidade de Lisboa: Lisboa, PT

Universidade de Lisboa: Lisboa, PT

Universidade de Lisboa: Lisboa, PT

Universitat de Barcelona: Barcelona, Catalunya, ES

Université Paris-Sud: Orsay, FR

Education and qualifications (1)

Universidade Nova de Lisboa: Lisboa, PT

Funding (14)

Potencial de derivados de ácido nitrobenzóico como fármacos antituberculose. Insights sobre o mecanismo de ação.

ITN "Protease-guided tumor targeting tools to revolutionize cancer diagnosis and treatment" (Funding: 2,331,266.4 )

Targeting mutant p53 with tryptophanol-derived small molecules (Funding: 249.956,25)

Bilateral Action Portugal-Hungary, Design and synthesis of hybrid compounds with enhanced anti-tumor potential

A new approach to fight tuberculosis: co-drugs activated by mycobacterial esterases

Tackling multidrug resistance in cancer: plant-derived lead compounds as P-glycoptrotein (P-gp) and breast cancer resistant protein (BCRP) modulators and collateral sensitivity agents

Drug discovery for p53 PPI-targets

Targeting p53 family proteins: on the route to new anticancer agents

Synthetic Process Development and Characterization of HOV14-731, an Active Pharmaceutical Ingredient (API) of the anti-muscarinic class

New Drugs to Treat Non-alcoholic Fatty Liver and Progression to Cancer

Determinação do diagrama ternário do HO20

Optimização de moduladores da glicoproteína-P e investigação do mecanismo de efluxo

Strategic Project - UI 4013 - 2011-2012

Diterpenes as lead compounds for overcoming multidrug resistance in cancer cells: P-glycoprotein modulators and antiproliferative agents

Works (50 of 92)

Structural optimization of indolizinoindolones to obtain potent new antimalarials with dual stage activity

Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol

In vitro antileishmanial activity of tryptophanol derivatives

Hybrid molecules of protoflavones and spirooxindole derivatives with selective cytotoxicity against triple-negative breast cancer cells

Reativação da p53 Usando Pequenas Moléculas para Terapia Anticancerígena

Antimalarial drugs: what’s new in the patents?

Metabolism-Guided Optimization of Tryptophanol-Derived Isoindolinone p53 Activators

Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors

Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity

Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis

Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis

Pharmacological Treatment of Malaria

Synthesis of spirooxindoles by multicomponent reactions

Abstract P030: Chemoprevention by the mutant p53 reactivator SLMP53-2 on ultraviolet radiation-induced skin cancer

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

Tryptophanol-Derived Oxazolopyrrolidone Lactams as Potential Anticancer Agents against Gastric Adenocarcinoma

Exploiting the antiproliferative potential of spiropyrazoline oxindoles in a human ovarian cancer cell line

PPIs as therapeutic targets for anticancer drug discovery: the case study of MDM2 and BET bromodomain inhibitors

Optimizing the oxazoloisoindolinone family: Identification and biological evaluation of a potent and selective indole-based p53 activator in human colorectal cancer

Potency and selectivity optimization of tryptophanol-derived oxazoloisoindolinones: novel p53 activators in human colorectal cancer

Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders

SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations

SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner

Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment

SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma

A Novel Small Molecule p53 Stabilizer for Brain Cell Differentiation

An Update on MDMX and Dual MDM2/X Inhibitors

Improving anticancer activity towards colon cancer cells with a new p53-activating agent

A More Sustainable Process for Preparation of the Muscarinic Acetylcholine Antagonist Umeclidinium Bromide

Process for the preparation of Umeclidinium bromide (WO/2018/087561 A1 20180517)

DIMP53-1: A novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties

In vitro targeting of colon cancer cells using spiropyrazoline oxindoles

Optimization of Bicyclic Lactam Derivatives as NMDA Receptor Antagonists

Spirotriazoline oxindoles: A novel chemical scaffold with in vitro anticancer properties

Asymmetric Cyclocondensation Reaction Induced by Chiral Auxiliary

Chemical variations on the p53 reactivation theme

Enantiopure indolo[2,3-a]quinolizidines: Synthesis and evaluation as NMDA receptor antagonists

Novel squaramides with in vitro liver stage antiplasmodial activity

Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule

Spirooxadiazoline oxindoles with promising in vitro antitumor activities

Synthesis of a spiroisoxazoline oxindole by 1,3-dipolar Cycloaddition